Details for Patent: 10,086,047

Which drugs does patent 10,086,047 protect, and when does it expire?

Patent 10,086,047 protects RYBELSUS and is included in one NDA.

This patent has thirty-eight patent family members in twenty-one countries.

Summary for Patent: 10,086,047

Title:	Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Abstract:	The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
Inventor(s):	Per Sauerberg, Simon Bjerregaard, Flemming S. Nielsen
Assignee:	Novo Nordisk AS
Application Number:	US15/019,412
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,086,047
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 10,086,047

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-001	Sep 20, 2019		RX	Yes	Yes	10,086,047		Y
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-002	Sep 20, 2019		RX	Yes	Yes	10,086,047		Y
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-003	Sep 20, 2019		RX	Yes	Yes	10,086,047		Y

Foreign Priority and PCT Information for Patent: 10,086,047

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	10195285	Dec 16, 2010

International Family Members for US Patent 10,086,047

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011343190
Brazil	112013014942
Canada	2821886
China	103260608
China	105963685